MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, PLRX had $6,912K increase in cash & cash equivalents over the period. -$21,081K in free cash flow.

Cash Flow Overview

Change in Cash
$6,912K
Free Cash flow
-$21,081K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-26,301 -99,466
Depreciation expense
436 895
Stock-based compensation expense
6,418 15,291
Gain on sale of property plant and equipment
44 -
Non-cash operating lease expense
821 1,628
Net amortization (accretion) on short-term investments and debt
-335 -3,339
Prepaid expenses and other current assets
-780 -1,970
Other non-current assets
0 -43
Accounts payable
-897 -4,580
Accrued liabilities
-2,031 -8,622
Operating lease liabilities
-598 35
Net cash used in operating activities
-21,081 -89,467
Purchase of short-term investments
52,563 65,756
Maturity of short-term investments
80,328 170,731
Purchase of property and equipment
0 374
Proceeds from sale of property, plant and equipment
156 -
Net cash provided by investing activities
27,921 104,601
Proceeds from issuances of common stock under benefit plans
72 498
Proceeds from term loan, net of issuance costs
0 0
Net cash provided by financing activities
72 498
Net increase in cash and cash equivalents
6,912 15,632
Cash and cash equivalents at beginning of period
72,670 -
Cash and cash equivalents at end of period
95,214 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

PLIANT THERAPEUTICS, INC. (PLRX)

PLIANT THERAPEUTICS, INC. (PLRX)